In these cases, a research experience by Noris et al. demonstrated that the quantification of the S100B level is an useful variable in the early identification or diagnosis of these neuropsychiatric manifestations in the course of infection or after damage to the post-COVID-19 CNS [58] (Figure 3). This evidence concerns the gene S100B and COVID-19.